Advanced search
Add to list

Intratumoral delivery of mRNA : overcoming obstacles for effective immunotherapy

(2015) ONCOIMMUNOLOGY. 4(5).
Author
Organization
Abstract
The immunosuppressive tumor microenvironment (TME) is a major obstacle in cancer immunotherapy. Therefore, it has gained attention as a target site. mRNA emerged as a versatile drug class for cancer therapy. We reported that intratumoral administration of mRNA encoding the fusokine F-2 supports tumor-specific T-cell immunity. This study provides proof of concept of the use of mRNA to modulate the TME.
Keywords
dendritic cell, CD8(+) T cell, fusokine, immunotherapy, intratumoral, IFN beta, mRNA, TGF beta receptor II, CANCER-THERAPY

Citation

Please use this url to cite or link to this publication:

MLA
Van Der Jeught, Kevin, Sandra Van Lint, Kris Thielemans, et al. “Intratumoral Delivery of mRNA : Overcoming Obstacles for Effective Immunotherapy.” ONCOIMMUNOLOGY 4.5 (2015): n. pag. Print.
APA
Van Der Jeught, K., Van Lint, S., Thielemans, K., & Breckpot, K. (2015). Intratumoral delivery of mRNA : overcoming obstacles for effective immunotherapy. ONCOIMMUNOLOGY, 4(5).
Chicago author-date
Van Der Jeught, Kevin, Sandra Van Lint, Kris Thielemans, and Karine Breckpot. 2015. “Intratumoral Delivery of mRNA : Overcoming Obstacles for Effective Immunotherapy.” Oncoimmunology 4 (5).
Chicago author-date (all authors)
Van Der Jeught, Kevin, Sandra Van Lint, Kris Thielemans, and Karine Breckpot. 2015. “Intratumoral Delivery of mRNA : Overcoming Obstacles for Effective Immunotherapy.” Oncoimmunology 4 (5).
Vancouver
1.
Van Der Jeught K, Van Lint S, Thielemans K, Breckpot K. Intratumoral delivery of mRNA : overcoming obstacles for effective immunotherapy. ONCOIMMUNOLOGY. 2015;4(5).
IEEE
[1]
K. Van Der Jeught, S. Van Lint, K. Thielemans, and K. Breckpot, “Intratumoral delivery of mRNA : overcoming obstacles for effective immunotherapy,” ONCOIMMUNOLOGY, vol. 4, no. 5, 2015.
@article{6964729,
  abstract     = {The immunosuppressive tumor microenvironment (TME) is a major obstacle in cancer immunotherapy. Therefore, it has gained attention as a target site. mRNA emerged as a versatile drug class for cancer therapy. We reported that intratumoral administration of mRNA encoding the fusokine F-2 supports tumor-specific T-cell immunity. This study provides proof of concept of the use of mRNA to modulate the TME.},
  articleno    = {e1005504},
  author       = {Van Der Jeught, Kevin and Van Lint, Sandra and Thielemans, Kris and Breckpot, Karine},
  issn         = {2162-402X},
  journal      = {ONCOIMMUNOLOGY},
  keywords     = {dendritic cell,CD8(+) T cell,fusokine,immunotherapy,intratumoral,IFN beta,mRNA,TGF beta receptor II,CANCER-THERAPY},
  language     = {eng},
  number       = {5},
  pages        = {3},
  title        = {Intratumoral delivery of mRNA : overcoming obstacles for effective immunotherapy},
  url          = {http://dx.doi.org/10.1080/2162402X.2015.1005504},
  volume       = {4},
  year         = {2015},
}

Altmetric
View in Altmetric
Web of Science
Times cited: